{"id":11650,"date":"2020-05-27T17:02:32","date_gmt":"2020-05-27T21:02:32","guid":{"rendered":"https:\/\/www.bumc.bu.edu\/im-residency\/?page_id=11650"},"modified":"2020-05-27T17:02:32","modified_gmt":"2020-05-27T21:02:32","slug":"safety-of-recombinant-zoster-vaccine-in-patients-with-inflammatory-bowel-disease","status":"publish","type":"page","link":"https:\/\/www.bumc.bu.edu\/im-residency\/safety-of-recombinant-zoster-vaccine-in-patients-with-inflammatory-bowel-disease\/","title":{"rendered":"Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease"},"content":{"rendered":"

Venkata Satyam, MD<\/h3>\n
\n
\n
\n
\n

Abstract<\/strong><\/p>\n

Background <\/strong>Patients with inflammatory bowel disease (IBD) are at increased risk of developing herpes zoster. In October 2017, the FDA approved a two-dose adjuvanted, recombinant herpes zoster vaccine (RZV). There is a theoretical concern that vaccine adjuvants may cause flares in patients with immune-mediated diseases. We aimed to assess the rates of IBD flare and adverse reactions after administration of RZV in a cohort of patients with IBD.<\/span><\/p>\n

Methods <\/strong>We conducted a prospective observational study of patients with IBD who received RZV between February 2018 and July 2019 at a tertiary IBD referral center. IBD activity scores were collected from patients during o<\/span>ffi<\/span>ce visit or phone call after vaccination. The primary outcome was rate of IBD flare, defined as an increase in IBD activity, resulting in escala- tion of medical therapy, following vaccination. The secondary outcomes were rates of local and systemic adverse reactions after vaccination.<\/span><\/p>\n

Results <\/strong>We identified 67 patients (28 with ulcerative colitis and 39 with Crohn\u2019s disease) who received at least one dose of RZV. The two-dose vaccine series was completed by 55 patients (82%). Median duration of follow-up after vaccination was 207 days. One case of IBD flare was identified. No cases of herpes zoster were identified. Local and systemic adverse reactions were reported in 74.6% and 56.7% of patients, respectively.<\/span><\/p>\n

Conclusions <\/strong>In this cohort of 67 patients, a low rate of IBD flare (1.5%) was observed after RZV administration. Rates of local and systemic adverse reactions were comparable to those seen in the RZV clinical trials.<\/span><\/p>\n<\/div>\n

READ MORE<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Venkata Satyam, MD Abstract Background Patients with inflammatory bowel disease (IBD) are at increased risk of developing herpes zoster. In October 2017, the FDA approved a two-dose adjuvanted, recombinant herpes zoster vaccine (RZV). There is a theoretical concern that vaccine adjuvants may cause flares in patients with immune-mediated diseases. We aimed to assess the rates […]<\/p>\n","protected":false},"author":15816,"featured_media":0,"parent":0,"menu_order":114,"comment_status":"open","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/pages\/11650"}],"collection":[{"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/users\/15816"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/comments?post=11650"}],"version-history":[{"count":1,"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/pages\/11650\/revisions"}],"predecessor-version":[{"id":11654,"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/pages\/11650\/revisions\/11654"}],"wp:attachment":[{"href":"https:\/\/www.bumc.bu.edu\/im-residency\/wp-json\/wp\/v2\/media?parent=11650"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}